NSC745885
| 中文名称 | NSC745885 |
|---|---|
| 中文同义词 | 化合物 T16354 |
| 英文名称 | NSC745885 |
| 英文同义词 | NSC745885;NSC-745885,NSC745885;Anthra[1,2-c][1,2,5]thiadiazole-6,11-dione |
| CAS号 | 4219-52-7 |
| 分子式 | C14H6N2O2S |
| 分子量 | 266.27 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 4219-52-7.mol |
| 结构式 |  |
NSC745885 性质
| 沸点 | 470.0±14.0 °C(Predicted) |
|---|---|
| 密度 | 1.574±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：< 1 mg/mL（不溶或微溶） *NSC745885 通常配制为悬浮液。 |
| 酸度系数(pKa) | -1.90±0.20(Predicted) |
|
EZH2
|
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC 50 of NSC745885 is 0.85 μM after 72 hours’ treatment.NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.
Cell Viability Assay
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM |
| Incubation Time: | 24, 48, or 72 hours |
| Result: | Decreases SAS cells growth as a time and dose-dependent manner. |
Apoptosis Analysis
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM |
| Incubation Time: | 24 hours |
| Result: | Decreases SAS cells growth as a time and dose-dependent manner. |
Western Blot Analysis
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM |
| Incubation Time: | 24 or 48 hours |
| Result: | Increased cleaved caspase-3 expression and decreased XIAP expression. |
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.
| Animal Model: | Eight-week-old NOD/SCID (NOD.CB17 Prkdc scid /J) mice |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection; 2 mg/kg; once daily; 10 days |
| Result: | Inhibited engrafted tumors growth in vivo. |